Alphamab Oncology saw the highest growth of 0.32% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Alphamab Oncology’s patent filings and grants. Buy the databook here.
Alphamab Oncology has been focused on protecting inventions in European Patent Office(EPO) with two publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 50% of filings. The European Patent Office(EPO), United States(US), World Intellectual Property Organization(WIPO), and Canada(CA) patent Office are among the top ten patent offices where Alphamab Oncology is filings its patents. Among the top granted patent authorities, Alphamab Oncology has 100% of its grants in Canada(CA).
Regeneron Pharmaceuticals and Amgen could be the strongest competitors for Alphamab Oncology
Patents related to nanomedicine lead Alphamab Oncology's portfolio
Alphamab Oncology has the highest number of patents in nanomedicine. For nanomedicine, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Sepsis related patents lead Alphamab Oncology portfolio followed by fungal infections, and viral infections
Alphamab Oncology has highest number of patents in sepsis followed by fungal infections, viral infections, hepatitis b, and epstein–barr virus (hhv-4) infections.
For comprehensive analysis of Alphamab Oncology's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.